Inoviq Ltd (ASX: IIQ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Inoviq Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$59.81 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
92.02 million
Earnings per share
-0.098
Dividend per share
N/A
Year To Date Return
1.56%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Inoviq Ltd (ASX: IIQ)
Latest News
Healthcare Shares
What's going on with the Inoviq (ASX:IIQ) share price today?
Healthcare Shares
Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?
Share Gainers
BARD1 (ASX:BD1) share price ends stellar day up 41%
Healthcare Shares
BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news
Share Market News
BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update
Healthcare Shares
Here's why the BARD1 (ASX:BD1) share price is falling 7% today
Share Fallers
Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking
Capital Raising
BARD1 (ASX:BD1) share price falls 6% on placement update
Share Market News
Here's why the BARD1 (ASX:BD1) share price is frozen today
Healthcare Shares
Why the BARD1 (ASX:BD1) share price is surging 10% higher
Share Fallers
Why the BARD1 (ASX:BD1) share price plummeted 9% today
Healthcare Shares
Here's why the BARD1 (ASX:BD1) share price is crushing it today
1❯
IIQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Inoviq Ltd
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
IIQ Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 08 Dec 2023 | $0.65 | $0.03 | 4.84% | 57,320 | $0.62 | $0.65 | $0.62 |
| 07 Dec 2023 | $0.62 | $0.01 | 1.63% | 25,610 | $0.62 | $0.64 | $0.62 |
| 06 Dec 2023 | $0.62 | $0.00 | 0.00% | 43,647 | $0.62 | $0.64 | $0.62 |
| 05 Dec 2023 | $0.62 | $-0.02 | -3.15% | 7,517 | $0.64 | $0.64 | $0.62 |
| 04 Dec 2023 | $0.64 | $0.05 | 8.47% | 29,284 | $0.61 | $0.64 | $0.60 |
| 01 Dec 2023 | $0.59 | $0.01 | 1.72% | 47,541 | $0.58 | $0.60 | $0.58 |
| 30 Nov 2023 | $0.58 | $-0.03 | -4.92% | 79,721 | $0.60 | $0.60 | $0.58 |
| 29 Nov 2023 | $0.61 | $0.02 | 3.39% | 30,520 | $0.58 | $0.61 | $0.58 |
| 28 Nov 2023 | $0.59 | $0.01 | 1.71% | 120,521 | $0.59 | $0.59 | $0.56 |
| 27 Nov 2023 | $0.59 | $-0.04 | -6.40% | 42,412 | $0.64 | $0.64 | $0.59 |
| 24 Nov 2023 | $0.63 | $0.03 | 5.04% | 39,153 | $0.60 | $0.63 | $0.59 |
| 23 Nov 2023 | $0.60 | $-0.01 | -1.67% | 54,875 | $0.60 | $0.60 | $0.59 |
| 22 Nov 2023 | $0.60 | $0.03 | 5.22% | 11,852 | $0.59 | $0.60 | $0.58 |
| 20 Nov 2023 | $0.58 | $-0.03 | -5.00% | 10,169 | $0.58 | $0.61 | $0.58 |
| 17 Nov 2023 | $0.60 | $-0.02 | -3.25% | 60,179 | $0.62 | $0.64 | $0.60 |
| 16 Nov 2023 | $0.62 | $-0.03 | -4.65% | 39,554 | $0.64 | $0.64 | $0.62 |
| 15 Nov 2023 | $0.65 | $0.05 | 8.33% | 29,797 | $0.60 | $0.65 | $0.60 |
| 14 Nov 2023 | $0.60 | $0.01 | 1.68% | 64,851 | $0.60 | $0.62 | $0.60 |
| 13 Nov 2023 | $0.60 | $-0.01 | -1.67% | 7,117 | $0.60 | $0.60 | $0.60 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 06 Mar 2023 | Philip (Phil) Powell | Buy | 20,000 | $11,400 |
On-market trade.
|
| 03 Mar 2023 | Philip (Phil) Powell | Buy | 19,481 | $10,909 |
On-market trade.
|
| 02 Mar 2023 | Philip (Phil) Powell | Buy | 20,000 | $11,200 |
On-market trade.
|
| 01 Mar 2023 | Philip (Phil) Powell | Buy | 18,518 | $9,999 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David Williams | Non-Executive ChairmanNon-Executive Director | Nov 2023 |
--
|
| Mr Philip (Phil) John Powell | Non-Executive Director | Jun 2019 |
Mr Powell has experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles.
|
| Mr Geoffrey A. Cumming | Non-Executive ChairmanNon-Executive Director | Jul 2020 |
Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the growing and profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was in designing and securing key funding arrangements through a range of capital raising initiatives, including government grants, partnering and co-development deals. He is Member of Risk Committee.
|
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | Jun 2019 |
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. He is Member of Risk Committee.
|
| Dr Leearne Hinch | Chief Executive Officer | Nov 2016 |
-
|
| Mr Mark Edwards | Chief Financial OfficerCompany Secretary | Nov 2022 |
-
|
| Leearne Hinch | Chief Executive Officer |
-
|
|
| Mark Edwards | Chief Financial OfficerCompany Secretary |
-
|
|
| Dr Gregory Rice | Chief Scientific Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| The Trust Company Australia Limited <Mof A/C> | 6,457,000 | 7.02% |
| Dr Irmgard Irminger Finger | 3,445,829 | 3.74% |
| Lawn Views Pty Ltd <Angela Williams Family A/C> | 2,676,924 | 2.91% |
| The Trust Company (Australia) Limited <Mbf A/C> | 2,248,333 | 2.44% |
| Moggs Creek Pty Ltd <Moggs Creek Super A/C> | 2,209,747 | 2.40% |
| Lesamourai Pty Ltd | 2,000,000 | 2.17% |
| BNP Paribas Nominees Pty Ltd <IB AU NOMS Retailclient DRP> | 1,956,453 | 2.13% |
| J P Morgan Nominees Australia Pty Limited | 1,508,353 | 1.64% |
| Mr Peter William Rogers & Ms Alida Johanna Clark <R&C Super Fund A/C> | 1,217,245 | 1.32% |
| Traoj Pty Ltd <Traoj A/C> | 1,102,933 | 1.20% |
| Supergun Pty Ltd <Bricklanding Super Fund A/C> | 1,030,000 | 1.12% |
| Mr Nathan Ryan Wagner | 1,010,562 | 1.10% |
| Mr Adam Garrigan | 1,000,000 | 1.09% |
| David Neate | 902,257 | 0.98% |
| Trovex Pty Ltd | 820,000 | 0.89% |
| Dr Russell Kay Hancock | 750,000 | 0.82% |
| Citicorp Nominees Pty Limited | 717,669 | 0.78% |
| B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> | 600,000 | 0.65% |
| Ll&P Pty Ltd <The Andrew Solomons S/F A/C> | 584,095 | 0.63% |
| P R Perry Nominees Pty Ltd <Donesk Family A/C> | 561,000 | 0.61% |
